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Two endothelial cell growth factors have been isolated from human brain extracts by a procedure involving 
heparin-Sepharose affinity chromatography and reverse-phase HPLC. On the basis of molecular size. amino 
acid composition and extended amino-terminal sequences, the two proteins are structurally closely related 
to bovine acidic and basic fibrobtast growth factors (aFGF, bFGF). The N-terminal sequences of human 
and bovine aFGF differ in two positions while those for bFGF are indistinguishable. Human aFGF is mi- 
croheterogenous: in addition to aFGF two N-terminally truncated forms lacking the first and the seven first 
amino acids, respectively, were characterized, Human and bovine mitogens possess imilar mitogenic activi- 
ties. 
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1. INTRODUCTION 
Two potent mitogens, acidic fibroblast growth 
factor (aFGF) and basic FGF (bFGF), have recent- 
ly been isolated from bovine brain and pituitary 
and characterized by complete sequence analysis 
[l-6]. The two factors are potent mitogens for a 
wide variety of neuroectoderm- and mesoderm- 
derived cells in vitro and are angiogenic in vivo. 
Earlier data have also demonstrated the existence 
of human acidic and basic FGFs. The available 
data (affinity for heparin [7], amino acid composi- 
tions [8-IO], a short N-terminal sequence of 
human bFGF [8]) suggest that the human and 
bovine bFGFs are structurally closely related. We 
now report the further chemical (N-terminal se- 
quence) and biological characterization of human 
brain aFGF and demonstrate that this protein is 
isolated as several microheterogenous forms. Since 
* To whom correspondence should be addressed 
aFGF and bFGF can be purified to homogeneity 
from the same batch of brain tissue, we also show 
an extended amino-terminal sequence of human 
bFGF. 
2. MATERIALS AND METHODS 
2.1. Zsolation 
Human brains (12-18 h post-mortem) were 
stored at -80°C until use. FGFs were isolated as 
in [4]. Briefly, human brains were processed (2 
batches of 1.4 and 3.6 kg) by extraction in 0.15 M 
~moni~ sulfate, pH 4.5, ~mo~urn sulfate 
precipitation, cation-exchange chromatography, 
heparin-Sepharose affinity chromatography, and 
reverse-phase HPLC. 
2.2. Structural characterization 
A& values of the growth factors were determined 
by SDS polyacrylamide gel electrophoresis as 
described [ 111. Proteins were visualized by silver 
staining (Bio-Rad reagent kit and procedure). 
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Amino acid analyses were performed with 
10-20 pmol protein on a Chromakon 500 amino 
acid analyzer (Kontron, Ziirich) equipped with an 
ophthalaldehyde fluorescence detection system 
[ 121. Results were not corrected for hydrolysis 
losses. 
Heparin-Sepharose fractions (l-5 nmol FGF) 
were reduced and alkylated as follows: samples 
were deaerated with argon, reduced with 
dithiothreitol @-fold molar excess over protein 
cysteine content) in 0.5 M Tris-Cl, pH 8.6/10 mM 
EDTA/6 M guanidine hydrochloride (final con- 
centrations) under argon at room temperature for 
2 h, and alkylated by adding iodo[2-‘4C]acetic acid 
(3-fold molar excess over total SH in the reduced 
sample solution) under argon for 30 min at room 
temperature in the dark. Alkylated proteins were 
purified by reverse-phase HPLC (see fig. 1 for con- 
ditions). Aliquots of chromatography fractions 
were counted in a Beta-Matic beta-counter 
(Kontron). 
Sequence analyses of native and/or alkylated 
FGFs were carried out using an Applied 
Biosystems gas/liquid phase microsequenator with 
experimental protocols for sequencing and HPLC 
identification of phenylthiohydantoin (PTH) 
amino acids as supplied by the manufacturer. 
2.3. Bioassay 
The mitogenic activity of column fractions was 
determined using cultured bovine aortic en- 
dothelial (ABAE) cells as described [l,l I]. Cells 
were seeded at low density (20000 cells/35 mm 
dish) in Dulbecco’s modified Eagle’s medium 
(DMEM) cont~ning 10% calf serum (Hyclone 
Sterile Systems, Logan, UT). Cells were grown for 
5-6 days in the presence of sample aliquots (added 
on days 0 and 2), trypsinized, and counted in a 
Coulter particle counter. 
3. RESULTS AND DISCUSSION 
Human FGFs were purified to near homogeneity 
by heparin-Sepharose affinity chromatography 
with results similar to those in [4,8]. Mitogenic 
material subsequently identified as aFGF and 
bFGF (see below) eluted from the column at 
1.0-1.2 and 1.4-1.6 M NaCl, respectively. 
Reverse-phase HPLC of aliquots of heparin- 
Sepharose column fractions containing either 
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Fig. 1. Reverse-phase HPLC of heparin-sepharose- 
purified FGFs. Chromatography conditions: Vydac C4 
column (25 x 0.46 cm, 5 pm partides, 300 A pores, The 
Separation Group, Hesperia, CA), 60 min gradient of 
2540% acetonitrile in 0.1% trifluoroacetic acid, flow 
0.6 mb’min. (A) aFGF, aliquot of pool of fractions 
eluting at 1.0-l .2 M NaCI. (B) bFGF, aliquot of pool of 
fractions eluting at 1.4-1.6 M NaCI. 
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Fig.2. SDS gel electrophoresis of heparin-sepharose- 
purified FGFs. Lanes: (1) M, markers (bovine serum 
albumin, M, 66200; ovalbumin, &f, 4.5ooO; carbonic 
anhydrase, &f, 31 Ooo; trypsin inhibitor, Iw, 21500; 
lysozyme, n/l, 14400); (2) bovine pituitary bFGF; (3) 
human bFGF; (4) human aFGF; (5) bovine brain aFGF. 
40-80 ng protein was applied to each lane. 
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Table I 
_ N-terminal amino acid sequences of human acidic and basic FGFs 
1 10 20 30 
aFGF: human A (batch l)a 1;; NLPPGNYKI;P KLLYxSNGiH FLRILPDG;V DGT - 
human B (batch 2)b NLPPGNYKKP KLLYCSNGGH FLRILPDGxV D- 
human C (batch 2)b YKKP KLLYCSNGGH FLRILPDGTV D - 
bovine F NLPLGNYKKP KLLYCSNGGY FLRILPDGTV DGT - 
* * 
bFGF: humanC PALPEDGGSG AFPPGHFKDP KRLY xKNGGF FLRfxP- 
bovine PALPEDGGSG AFPPGHFKDP KRLYCKNGGF FLRIHPDGRV D - 
l . l 
1 ;0 20 30 4b 
aSOO pmol HPLC-purified native aFGF from batch 1 
900 pmol HPLC-purified alkylated aFGF from batch 2. The sequenced material consisted of two proteins, human B 
(main sequence) and human C 
%O pmol HPLC-purified bFGF from batch 2 
(x) PTH-amino acid not identified. *Established differences between human and bovine FGF sequences. For all analyses 
initial yields were 49-60%, average repetitive yields: 93.3-94.9%. Bovine sequences from [2,6] 
aFGF or bFGF is shown in fig.1. Approx, 16 and 
4 nmol homogeneous aFGF and bFGF, respective- 
ly, were isolated from 1 kg brain tissue (as deter- 
mined by amino acid analysis). 
&f, values of heparin-Sepharose-purified protein 
fractions were established by gel electrophoresis 
(fig.2). Human and bovine aFGFs (lanes 4,5) 
migrated as doublets. In the case of bovine aFGF 
the doublet bands are known to correspond to 
aFGF (upper band, M, 16000, 140 residues) and to 
an N-terminally truncated des( l-6)-aFGF (un- 
published and [5,6]). Therefore, comparison of the 
migration of human aFGF to the bovine FGFs of 
known sizes rather accurately indicates that human 
aFGF (lane 4, upper band) has an Mr of approx. 
16500 and consists of 144-145 amino acid 
residues. Although no direct proof is available, it 
is likely on the basis of sequencing results (see 
below) that the lower band of the human aFGF 
doublet also corresponds to a truncated aFGF 
form. Heparin-Sepharose-purified human bFGF, 
on the other hand, shows one major band (with a 
minor contaminating band of unknown nature) on 
gel electrophoresis. Comparison of human and 
bovine bFGFs suggests that the human protein is 
very similar in size to the known bovine mitogen 
(A& 16500, 146 residues). 
Amino acid compositions were determined for 
human aFGF as Asx(14.3), Thr(7.3), Ser(8.9), 
Glx(15.8), Gly(15.3), Ala(4.6), Va1(5.2), Met(0.8), 
Ile(4.9), Leu(18.3), Tyr(7.1), Phe(4.9), His(5.2), 
Lys(9.6), Arg(7.1) and for human bFGF as 
Asx(13.9), Thr(6.7), Ser(8.3), Glx( 11.7), 
Gly(l5.1), Ala(8.6), Val(7.0), Met(d.O), lle(4.6), 
Leu(l4.0), Tyr(6.4), Phe(7.1), His(3.3), Lys(l1.7), 
Arg(9.7) (Pro was not determined, Cys and Trp 
only qualitatively determined). These amino acid 
compositions are very similar to those of the 
bovine mitogens [8-IO]. The results from N- 
terminal sequence analyses of acidic and basic 
FGFs are shown in table 1. Sequence analysis of 
aFGF obtained from two isolation batches in- 
dicated that isolated aFGF can occur in several 
molecular forms: one isolation (batch I) produced 
the N-terminal sequence aFGF human A (table 1) 
which aligns exactly with the known bovine se- 
quence. In another isolation (batch 2) the purified 
aFGF actually consisted of a mixture of two 
related FGF proteins which could not be separated 
by HPLC in either their native or alkylated forms 
under the conditions used. Although two PTW- 
amino acid derivatives were identified in each se- 
quencer cycle, unambiguous assignment of both 
sequences was possible because of the presence of 
a 2-fold excess of the amino acid derivatives arising 
from the main constituent in the mixture and 
because of previous knowledge of the N-terminal 
sequence of human aFGF (sequencing of batch 1). 
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Sequencing indicated that the main product 
(human B, table 2) is an aFGF that lacks the N- 
terminal Phe residue (des-Pher-aFGF). The minor 
sequence (human C) was also found to correspond 
to an N-terminally truncated aFGF (des(l-7)- 
aFGF). The N-terminal sequence of human aFGF 
differs from that of the bovine mitogen by the 
replacement of two amino acids (table 2). Human 
brain bFGF, on the other hand, does not differ 
from bovine bFGF in the extended N-terminal 
region. 
Thus, human and bovine aFGFs clearly differ in 
structure with respect to size and at least the N- 
terminal sequence. In contrast, human and bovine 
bFGFs are indistinguishable with respect to all 
structural criteria employed. In this context is it 
noteworthy that bFGFs purified from other 
human tissues (cartilage, hepatoma) possess higher 
M, values of 18000-19000 [lo]. 
Heparin-Sepharose-purified human aFGF and 
bFGF are capable of stimulating the proliferation 
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Fig.3. Mitogenic activity of human FGFs. to-p1 aliquots 
cont~ning increasing amounts of heparin-Seph~ose- 
purified aFGF (e) and bFGF (0), diluted in 
DMEM/OSolo bovine serum albumin, were added to 
ABAE and growth assayed as described in section 2. 
Maximal stimulation of cells with bovine bFGF (1 ng/ml 
given twice) results in cell counts of 1 X lo6 cells/35 mm 
dish. Error bars indicate range of duplicate values. 
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